Molecular Features of Gastrointestinal Stromal Tumors: A Single Referral Cancer Center Experience
<h3>Background/Aim:</h3> Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the digestive tract. They frequently harbor mutations in KIT proto-oncogene, receptor tyrosine kinase (<i>KIT</i>) (70-80%) and platelet-derived growth factor receptor alpha (<i>PDGFRA</i>) (10-15%) genes, responding effectively to tyrosine kinase inhibitors (TKIs). Accurate genotyping is crucial for diagnosis and therapeutic management. This study reports a decade-long experience, detailing the epidemiological, pathological, and molecular characteristics of GISTs in a single-center cohort. <h3>Patients and Methods:</h3> Twenty-nine patients diagnosed with GIST (stomach, small bowel, colon, and peritoneum) at IRCCS CROB, Italy, between 2012 and 2021 were enrolled. Molecular analysis was performed using Sanger sequencing and Next-Generation Sequencing (NGS). <h3>Results:</h3> Twenty-three patients (85%) harbored <i>KIT</i> mutations, while four (15%) had <i>PDGFRA</i> mutations. Among <i>KIT</i>-mutated cases, five (22%) presented the p.Ala502_Tyr503dup duplication in exon 9. Elevated Ki-67 and a mitotic index of 3-7/50 high-power field (HPF) were associated with high recurrence risk. Eighteen patients (78%) exhibited mutations in exon 11: 8 (44%) were point mutations, 5 (28%) deletions, and 5 (28%) complex deletions. Point mutations at codons 557, 560, and 603 correlated with high recurrence risk, whereas mutations at codons 559 and 599 linked to low-risk disease. Most deletions and complex deletions showed high recurrence risk and Ki-67 >10%. <i>PDGFRA</i> mutations were located in exon 18 (2 complex deletions, 2 point mutations including p.D842V); three of these cases showed low-to-moderate recurrence risk (Ki-67 ≤8%). <h3>Conclusion:</h3> This study characterizes the clinicopathological and molecular profiles of 29 Caucasian GIST patients, reinforcing the critical role of molecular stratification in clinical practice.
Authors
- Ludmila Carmen Omer (ORCID: https://orcid.org/0009-0006-8145-9535)
- Angela Zupa
- Giovanni Calice (ORCID: https://orcid.org/0000-0002-2545-1401)
- Giulia Vita (ORCID: https://orcid.org/0000-0002-1060-0160)
- Giuseppina Improta (ORCID: https://orcid.org/0000-0001-5175-5903)
- Alfredo Tartarone (ORCID: https://orcid.org/0000-0002-0859-7847)
Institutions
- Centro di Riferimento Oncologico della Basilicata (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- Anticancer Research
- Published
- 2026-05-27
- DOI
- https://doi.org/10.21873/anticanres.18180
- Primary Topic
- Gastrointestinal Tumor Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministero della Salute